Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Dermira, Inc. (DERM) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/20/2020 8-K Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligati...
Docs: "Amended and Restated Certificate of Incorporation of Dermira, Inc",
"Amended and Restated Bylaws of Dermira, Inc",
"First Supplemental Indenture, between Dermira, Inc. and U.S. Bank National Association"
01/10/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger by and among Eli Lilly, Bald Eagle Acquisition Corporation and Dermira, Inc.",
"Tender and Support Agreement, by and among Eli Lilly and Company, Bald Eagle Acquisition Corporation, New Enterprise Associates 13, L.P. and NEA Ventures 2011, Limited Partnership",
"Tender and Support Agreement, by and among Eli Lilly and Company, Bald Eagle Acquisition Corporation, Bay City Capital Fund V, L.P., Bay City Capital Fund V Co-Investment Fund, L.P. and Bay City Capital LLC",
"Lilly Announces Agreement to Acquire Dermira Lilly to acquire Dermira for $1.1 billion, expanding its portfolio of Phase 3 medicines with the addition of lebrikizumab, an IL-13antibody being studied in Phase 3 for the treatment of moderate-to-severe atopic dermatitis"
11/13/2019 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update"
10/09/2019 8-K Quarterly results
08/07/2019 8-K Quarterly results
Docs: "FORM 8-K",
"Dermira Reports Second Quarter 2019 Financial Results and Provides Corporate Update"
06/25/2019 8-K Other Events
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : June 24, 2019 DERMIRA, INC. Delaware 001-36668 27-3267680 275 Middlefield Road, Suite 150 Menlo Park, California 94025 Registrant's telephone number, including area code: 421-7200 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre..."
06/10/2019 8-K Submission of Matters to a Vote of Security Holders
Docs: "FORM 8-K"
05/07/2019 8-K Quarterly results
Docs: "Dermira Reports First Quarter 2019 Financial Results and Provides Corporate Update"
03/20/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Underwriting Agreement",
"Opinion of Fenwick & West LLP",
"Dermira Prices $130.0 Million Public Offering of Common Stock"
03/18/2019 8-K Other Events
Docs: "FORM 8-K"
03/18/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : March 18, 2019 Dermira, Inc. Delaware 001-36668 27-3267680 275 Middlefield Road, Suite 150 Menlo Park, California 94025 421-7200 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e...",
"Dermira Announces Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis",
"Dermira, Inc. Presentation"
02/28/2019 8-K Quarterly results
02/26/2019 8-K Quarterly results
02/12/2019 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab"
01/07/2019 8-K Other Events
12/04/2018 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Dermira Enters into Credit Facility with Athyrium Capital Management"
11/07/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Dermira Reports Third Quarter 2018 Financial Results"
10/01/2018 8-K Quarterly results
09/05/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Dermira Provides Launch Readiness Update for QBREXZA™ Cloth for Primary Axillary Hyperhidrosis"
08/06/2018 8-K Quarterly results
Docs: "Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update"
06/29/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Dermira Receives FDA Approval for Qbrexza™ Cloth to Treat Primary Axillary Hyperhidrosis"
06/18/2018 8-K Submission of Matters to a Vote of Security Holders
05/24/2018 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Investor Presentation",
"Investor Presentation"
05/03/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of report : May 3, 2018 DERMIRA, INC. Delaware 001-36668 27-3267680 275 Middlefield Road, Suite 150 Menlo Park, California 94025 Registrant's telephone number, including area code: 421-7200 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-c...",
"Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update"
03/05/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints"
02/22/2018 8-K Quarterly results
Docs: "FORM 8-K",
"Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update"
11/06/2017 8-K Quarterly results
Docs: "Dermira Reports Third Quarter 2017 Financial Results and Announces that FDA Accepts New Drug Application for Glycopyrronium Tosylate for the Treatment of Patients with Primary Axillary Hyperhidrosis"
11/06/2017 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Departure of Directors or Certain...
Docs: "Dermira and UCB Agree to End Collaboration Agreement for CIMZIA"
09/28/2017 8-K Quarterly results
08/08/2017 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Dermira Enters into Agreement to License Exclusive, Worldwide Rights to Lebrikizumab"
08/07/2017 8-K Quarterly results
Docs: "Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update"
06/19/2017 8-K Form 8-K - Current report
05/16/2017 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy